ViroMissile Clears First Dose Cohort in Phase I Cancer Virus Trial
Safety reviewers approved advancing to a higher dose after ViroMissile completed the first cohort of its intravenous oncolytic virus study.
ViroMissile, Inc. announced Wednesday that an independent Safety Review Committee has cleared its Phase I trial of IDOV-2 to advance to the next, higher dose cohort after completing the study's first group of patients. The San Diego-based cancer immunotherapy company said safety data from the initial cohort met the threshold required for escalation under the trial's protocol.
IDOV-2, formerly designated IDOV-Immune, is designed for intravenous delivery — a distinction the company says sets its oncolytic virus platform apart from treatments requiring direct tumor injection. The first-in-human study, registered as NCT06910657, enrolls patients with advanced solid tumors and represents a key early milestone in determining whether the intravenously deliverable approach is tolerable at escalating doses.
Read more Vima Therapeutics to Share Dystonia Research at 2026 Movement Disorders Congress →
The trial is being conducted across two countries, with sites operating in the United States and in Australia through ViroMissile's subsidiary, ViroMissile Australia, PTY, LTD. Conducting simultaneous international enrollment can accelerate patient accrual, a common strategy in early oncology trials where eligible populations are limited.
Advancement through dose-escalation cohorts in Phase I oncology studies is governed by safety signals rather than efficacy, and clearance by an independent committee is considered a meaningful procedural checkpoint. The next cohort will expose participants to higher doses of IDOV-2, with the Safety Review Committee expected to evaluate that group's data before any further escalation.
Continue reading at GlobeNewswire - Industry News on Financial Services.
